CX 614

Pricing Availability   Qty
Description: Positive allosteric modulator of AMPA receptors
Chemical Name: 2,3,6a,7,8,9-Hexahydro-11H-1,4-dioxino[2,3-g]pyrrolo[2,1-b][1,3]benzoxazin-11-one
Purity: ≥99% (HPLC)
Citations (3)
Literature (5)

Biological Activity for CX 614

CX 614 is an AMPAkine; positive allosteric modulator of AMPA. Prototypical benzamide which occupies subsite A only. Modulates channel deactivation and desensitization.

Compound Libraries for CX 614

CX 614 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for CX 614

M. Wt 247.25
Formula C13H13NO4
Storage Store at +4°C
Purity ≥99% (HPLC)
CAS Number 191744-13-5
PubChem ID 6451148
Smiles O=C2N4C(CCC4)OC1=CC3=C(OCCO3)C=C12

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for CX 614

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 24.73 100
ethanol 12.36 50

Preparing Stock Solutions for CX 614

The following data is based on the product molecular weight 247.25. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 4.04 mL 20.22 mL 40.44 mL
5 mM 0.81 mL 4.04 mL 8.09 mL
10 mM 0.4 mL 2.02 mL 4.04 mL
50 mM 0.08 mL 0.4 mL 0.81 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for CX 614

Certificate of Analysis / Product Datasheet
Select another batch:

References for CX 614

References are publications that support the biological activity of the product.

Harms et al (2013) Functional analysis of a novel positive allosteric modulator of AMPA receptors derived from a structure-based drug design strategy. Neuropharmacology 64 45 PMID: 22735771

Timm et al (2011) Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation. Mol.Pharmacol. 80 267 PMID: 21543522

Hennegriff et al (1997) Stable expression of recombinant AMPA receptor subunits: binding affinities and effects of allosteric modulators. J.Neurochem. 68 2424 PMID: 9166736

If you know of a relevant reference for CX 614, please let us know.

View Related Products by Target

View Related Products by Product Action

View all AMPA Receptor Modulators

Keywords: CX 614, CX 614 supplier, CX614, Positive, allosteric, modulators, AMPA, receptors, AMPAkines, benzamide, PAM, Receptors, 5149, Tocris Bioscience

3 Citations for CX 614

Citations are publications that use Tocris products. Selected citations for CX 614 include:

Susumu et al (2021) Gene-environment interactions mediate stress susceptibility and resilience through the CaMKIIβ/TARPγ-8/AMPAR pathway. iScience 24 102504 PMID: 34113835

Carolina da Silveira et al (2021) Respiratory depression and analgesia by opioid drugs in freely behaving larval zebrafish. Elife 10 PMID: 33720013

Ege T et al (2021) A subthreshold synaptic mechanism regulating BDNF expression and resting synaptic strength. Cell Rep 36 109467 PMID: 34348149

Do you know of a great paper that uses CX 614 from Tocris? Please let us know.

Reviews for CX 614

There are currently no reviews for this product. Be the first to review CX 614 and earn rewards!

Have you used CX 614?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.